Johnson & Johnson MedTech的动态

Interesting and very current article. As I always tell my clients, obesity is a multifactorial disease. It would not be correct to expect that a single treatment would be the magic solution. In the reality where I live and work, efforts aimed at prevention are precarious and lack the involvement of both the healthcare and education systems. In other words, prevention is still not a reality. At the same time, the cost of GLP-1 analogs remains a major obstacle. Even for the few who manage to use them, the effects after treatment suspension are often disappointing. Surgical intervention is still the most viable, reproducible option with the best medium- and long-term results.

When will you announce the end of your internal initiatives around DEI, LGBTQ and ESG? The vast majority of employees do not support the email propaganda they receive monthly. If they speak up they are put on paid leave and threaten with their job. It’s time to end this practice. Read the room, DEI was always discrimination to end discrimination.

Such an important conversation for best patient outcomes.